- Conditions
- Hemodialysis
- Interventions
- Sacubitril-valsartan, Placebo
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Diabetes Mellitus, Type 2, Pre-diabetic, Hypertension, Elevated Blood Pressure
- Interventions
- Sacubitril/Valsartan 200mg (blinded), Valsartan 160mg (blinded)
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Neoplasms
- Interventions
- [177Lu]-NeoB, [68Ga]-NeoB, LCZ696
- Drug
- Lead sponsor
- Advanced Accelerator Applications
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 6
- States / cities
- Duarte, California • Stanford, California • Baltimore, Maryland + 3 more
- Conditions
- Congenital Heart Disease
- Interventions
- Entresto Pill, Placebo
- Drug · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Pediatric Heart Failure
- Interventions
- LCZ696, Enalapril, Placebo of LCZ696, Placebo of Enalapril
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 1 Month to 17 Years
- Enrollment
- 393 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 25
- States / cities
- Loma Linda, California • Los Angeles, California • Palo Alto, California + 20 more
- Conditions
- Hypertension
- Interventions
- LCZ696, Olmesartan, LCZ696 matching placebo, Olmesartan matching placebo, amlodipine, hydrochlorothiazide
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 454 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 11
- States / cities
- Clearwater, Florida • Chicago, Illinois • Baltimore, Maryland + 8 more
- Conditions
- Diabetes Mellitus, Type 2, Diastolic Dysfunction
- Interventions
- LCZ 696, Placebos
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- LCZ696, Valsartan
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 4,822 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 110
- States / cities
- Huntsville, Alabama • Mobile, Alabama • Muscle Shoals, Alabama + 92 more
- Conditions
- Heart Failure
- Interventions
- sacubitril/valsartan
- Drug
- Lead sponsor
- Methodist Health System
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6,558 participants
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Acute Heart Failure
- Interventions
- sacubitril/valsartan (LCZ696), Enalapril, sacubitril/valsartan (LCZ696) matching placebo, enalapril matching placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 887 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 123
- States / cities
- Birmingham, Alabama • Fort Smith, Arkansas • Little Rock, Arkansas + 105 more
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- Entresto™ 49Mg-51 mg tablet
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Covid19
- Interventions
- Sacubitril / Valsartan Oral Tablet [Entresto], Placebo
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Heart Failure
- Interventions
- LCZ696, valsartan, LCZ696 placebo, valsartan placebo
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 365 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 38
- States / cities
- Beverly Hills, California • Sacramento, California • San Diego, California + 28 more
- Conditions
- Stage D Heart Failure
- Interventions
- Sacubitril-Valsartan, Usual care (standard-of-care) arm
- Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Heart Failure
- Interventions
- Sacubitril/valsartan, ACEi/ARB
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 42,269 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Systolic Hypertension
- Interventions
- LCZ696, Valsartan, AHU377, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 910 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 19
- States / cities
- Clearwater, Florida • Chicago, Illinois • Metairie, Louisiana + 12 more
- Conditions
- Heart Failure, Systolic
- Interventions
- Sacubitril/Valsartan
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 402 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Heart Failure
- Interventions
- LCZ696 (sacubitril/valsartan)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 794 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 77
- States / cities
- Birmingham, Alabama • Fort Payne, Alabama • Guntersville, Alabama + 66 more
- Conditions
- Chronic Heart Failure (CHF)
- Interventions
- LCZ696, Valsartan, Placebo of LCZ696, Placebo of Valsartan
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 592 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 52
- States / cities
- Andalusia, Alabama • Glendale, Arizona • Mesa, Arizona + 45 more
- Conditions
- Heart Failure
- Interventions
- ACE inhibitor, Sacubitril/Valsartan
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6,066 participants
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Heart Failure, Reduced Ejection Fraction
- Interventions
- sacubitril/valsartan (LCZ696), enalapril, matching placebo sacubitril/valsartan (LCZ696), matching placebo enalapril
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 23
- States / cities
- Fort Payne, Alabama • Beverly Hills, California • Stockton, California + 20 more
- Conditions
- Heart Failure With Reduced Ejection Fraction (HF-rEF)
- Interventions
- LCZ696
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Vero Beach, Florida
- Conditions
- Heart Failure
- Interventions
- Not listed
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,249 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Heart Failure With Preserved Ejection Fraction, Chronic Kidney Diseases
- Interventions
- MANP, Sacubitril/Valsartan, Oral Placebo, Injection Placebo
- Drug
- Lead sponsor
- Horng Chen
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota